Literature DB >> 16538156

Thymic hyperplasia after adjuvant chemotherapy in breast cancer.

Aasim S Sehbai1, Robert J Tallaksen, Jason Bennett, Jame Abraham.   

Abstract

We report 2 patients with breast cancer who were treated with surgery and adjuvant chemotherapy for stage IIa and stage I breast cancers. Follow-up CT scans showed an anterior mediastinal mass, raising concern for tumor recurrence. Thymectomy performed on the first patient, and close follow-up with radiographic studies on the second patient, revealed benign thymic enlargement. Thymic hyperplasia can occur after cytotoxic chemotherapy and may be due to rebound enlargement after initial atrophy caused by chemotherapy. Thymic hyperplasia after chemotherapy has been reported mostly in young age groups and is described in the literature to be associated with various types of cancers, including lymphomas, leukemias, testicular cancer, and sarcomas, and in the stem cell transplant setting. This is the first case series describing 2 patients with early stage breast cancer who, following adjuvant standard dose chemotherapy, developed thymic hyperplasia. Awareness of this unusual side effect in patients treated with chemotherapy may prevent unnecessary investigation and surgical intervention.

Entities:  

Mesh:

Year:  2006        PMID: 16538156     DOI: 10.1097/01.rti.0000185143.17436.f9

Source DB:  PubMed          Journal:  J Thorac Imaging        ISSN: 0883-5993            Impact factor:   3.000


  2 in total

Review 1.  Incidentally Visualization of the Thymus on Whole-Body Iodine Scintigraphy: Report of 2 Cases and Review of the Latest Insights.

Authors:  Mahdi Haghighatafshar; Farinaz Farhoudi
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

2.  Thymic hyperplasia after chemotherapy in adults with mature B cell lymphoma and its influence on thymic output and CD4(+) T cells repopulation.

Authors:  Dao-Ping Sun; Hui Jin; Chong-Yang Ding; Jin-Hua Liang; Li Wang; Lei Fan; Yu-Jie Wu; Wei Xu; Jian-Yong Li
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.